Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk.
暂无分享,去创建一个
Jianbo Li | Michael W Kattan | Elai Davicioni | Cristina Magi-Galluzzi | M. Kattan | C. Magi-Galluzzi | E. Klein | K. Yousefi | E. Davicioni | V. Choeurng | L. Lam | A. Stephenson | C. Buerki | Andrew J Stephenson | Eric A Klein | Beatrix Palmer-Aronsten | Z. Haddad | Jianbo Li | Christine Buerki | Zaid Haddad | Kasra Yousefi | Lucia L C Lam | Qiqi Wang | Voleak Choeurng | B. Palmer-Aronsten | Qiqi Wang
[1] David L Rimm,et al. Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer , 2015, Clinical Cancer Research.
[2] M. Cooperberg,et al. The CAPRA‐S score , 2011, Cancer.
[3] R. Tibshirani. The lasso method for variable selection in the Cox model. , 1997, Statistics in medicine.
[4] T. Lumley,et al. Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker , 2000, Biometrics.
[5] D. Firth. Bias reduction of maximum likelihood estimates , 1993 .
[6] F. Feng,et al. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. D'Amico,et al. Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer , 2015, Prostate Cancer and Prostatic Disease.
[8] M. Kattan,et al. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. , 2015, European urology.
[9] Michael W Kattan,et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] P. Febbo,et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. , 2014, European urology.
[11] L. Egevad,et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.
[12] M. Cooperberg,et al. A Straightforward Tool for Improved Prediction of Outcomes After Radical Prostatectomy , 2011 .
[13] B. Trock,et al. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. , 2016, European urology.
[14] P. Febbo,et al. The Impact of a Biopsy Based 17‐Gene Genomic Prostate Score on Treatment Recommendations in Men with Newly Diagnosed Clinically Prostate Cancer Who are Candidates for Active Surveillance , 2015, Urology practice.
[15] E. Klein,et al. Applying precision medicine to the active surveillance of prostate cancer , 2015, Cancer.
[16] M. Cooperberg,et al. Genomic Predictors of Outcome in Prostate Cancer. , 2015, European urology.